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Objectives. We evaluated the influence of the insertion/deletion
(I/D) polymorphism of the angiotensin I-converting enzyme
(ACE) gene on coronary plaque morphology and calcification in
patients with angiographically documented coronary artery dis-
ease (CAD).
Background. The ACE I/D polymorphism has been associated
with an increased risk of myocardial infarction in patients with
the DD genotype but not with the presence of native CAD.
Methods. We studied 146 patients undergoing percutaneous
transluminal coronary angioplasty for stable angina pectoris by
means of preinterventional intravascular ultrasound (IVUS).
Qualitative and quantitative criteria were used to classify the
target lesions as poorly or highly echoreflective or as calcified.
Genomic deoxyribonucleic acid was analyzed by polymerase chain
reaction (PCR) to identify the I/D polymorphism, with a second
insertion-specific PCR in DD genotypes to prevent mistyping.
Results. The ACE genotype groups (DD 46, ID 68, II 32) were
well matched for the basic characteristics. Patients with the DD
genotype had significantly more calcified lesions (DD 80%, ID
57%, II 66%; unadjusted odds ratio [OR] 2.88, 95% confidence
interval [CI] 1.30 to 6.92, p 5 0.008) and more calcifications
>180° of the vessel circumference (DD 22%, ID 10%, II 6%; OR
2.80, 95% CI 1.05 to 7.63, p 5 0.03). The prevalence of myocardial
infarction was not significantly associated with coronary calcifi-
cation (OR 1.44, 95% CI 0.72 to 2.88, p 5 0.31).
Conclusions. Patients with CAD and the ACE DD genotype
have a significantly higher incidence and greater extent of coro-
nary lesion calcification, as determined by IVUS. This finding
indicates that the ACE I/D gene polymorphism is related to the
development or progression of atherosclerotic plaque calcification.
(J Am Coll Cardiol 1998;31:987–91)
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The insertion/deletion (I/D) polymorphism of the angiotensin
I-converting enzyme (ACE) gene has been reported to be
associated with myocardial infarction (1,2) and, in some stud-
ies, with coronary artery disease (CAD) (3–5). However, these
results could not be confirmed in a large prospective trial (6)
and in a case-control study (7). A recent study in patients
undergoing coronary angiography suggested that the ACE I/D
polymorphism is not associated with CAD itself but was closely
associated with the occurrence of myocardial infarction (8).
Possible reasons for the discrepancies between these studies
may be selection bias in some studies (1–4,7,8) and the
different genetic backgrounds of the study populations. An-
other important reason for these discrepancies may be the use
of invasive or noninvasive methods for the assessment of
CAD (9).
Intravascular ultrasound (IVUS) is a new method for
detecting coronary atherosclerosis; its use enables transmural,
tomographic imaging of coronary arteries in humans in vivo.
This method allows the characterization of coronary plaque
composition, including calcium deposits, dense and loose
fibrous tissue and intimal hyperplasia (10,11). IVUS is espe-
cially useful in detecting the extent of in situ coronary calcium
(12). In symptomatic patients with CAD, calcification detected
on conventional fluoroscopy has been shown (13) to be asso-
ciated with an elevated risk of coronary events, and this
prognostic relevance of coronary calcification was independent
of age and gender.
The purpose of the present study was to use IVUS imaging
in human coronary arteries in vivo to analyze the association
among plaque morphology, extent of calcification and the ACE
I/D genotype in patients with severe CAD.
Methods
Patients. Between October 1994 and February 1996, a
series of 146 patients who were scheduled to undergo percu-
taneous transluminal coronary angioplasty were studied with
the use of preinterventional IVUS. Patients were selected from
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a cohort of 826 patients undergoing coronary angioplasty.
Selection criteria were stable angina pectoris during adequate
medication, absence of severe vessel tortuosity (no bend .90°
at the prestenotic, intrastenotic and post-stenotic lesion site)
and a reference vessel diameter .2 mm on angiography. The
patients had a mean age of 60.0 6 8.7 years (range 36 to 76);
116 were men, 30 women; and 86 had a history of myocardial
infarction. The basic characteristics of the study cohort are
provided in Table 1. The study was approved by the local ethics
committee, and written informed consent was obtained from
each patient before the procedure.
Ultrasound procedures. All patients underwent diagnostic
coronary angiography and coronary intervention according to
standard techniques. IVUS imaging was performed with a
commercially available intracoronary 3.2F monorail catheter
operating at 30 MHz (Cardiovascular Imaging Systems, Wies-
baden, Germany), accommodated by the 8F guiding catheter
used for coronary angioplasty. Before the coronary angio-
plasty, the IVUS catheter was advanced through the lesion of
interest; after it was positioned distal to this lesion, a slow,
manual, continuous pullback was performed. The gain control
settings were adjusted to provide an optimal dynamic range.
The ultrasound examination was recorded on S-VHS video-
tape, and the target lesion was analyzed by two independent
observers (A.A., K.R.K.) according to qualitative criteria.
Plaque composition was classified as (11–13) poorly echo-
reflective plaque if .80% of the plaque area was composed of
tissue with an echogenicity less than or equal to that of the
adventitia; highly echoreflective plaque if .80% of the plaque
area was composed of tissue producing echoes brighter than
that of the adventitia but without acoustic shadowing; and
calcified plaque if the plaque involved bright echoes with
acoustic shadowing ,90°, 90° to 180° or .180° of the vessel
wall circumference.
Laboratory methods. All blood samples were taken after
the patients had fasted overnight. Plasma total cholesterol and
triglyceride levels were measured by enzymatic methods
(Boehringer-Mannheim Biochemica, Mannheim, Germany),
and high density lipoprotein (HDL) cholesterol levels were
determined after sodium phosphotungstate/magnesium chlo-
ride precipitation. Low density lipoprotein (LDL) cholesterol
levels were calculated according to the Friedewald formula.
Genomic DNA was isolated and purified from whole blood
(from tubes containing EDTA) with the use of QIAamp spin
columns according to the manufacturer’s instructions
(QIAamp Blood Kit, QIAGEN GmbH, Hilden, Germany).
ACE genotypes were assessed by PCR using the primer
sequences and PCR cycling conditions as described previously
(14). The PCR fragments were separated on a horizontal 5%
polyacrylamide gel by electrophoresis and visualized by stain-
ing with silver solution. All gels were read by two independent
observers (M.P., P.C.). According to the absence or presence
of the 287-base pair insertion in the PCR product, the patients
were classified as homozygous DD, homozygous II or het-
erozygous ID. To prevent mistyping of ID as DD genotypes, a
second PCR with an insertion-specific primer was performed
with all samples classified as homozygous DD in the first PCR
(14,15). The investigators had no knowledge of the results of
the IVUS analysis.
Statistical analysis. Continuous variables are expressed as
mean values 6 SD for symmetric distributions and as median
Abbreviations and Acronyms
ACE 5 angiotensin I-converting enzyme
CAD 5 coronary artery disease
CI 5 confidence interval
D 5 deletion
DNA 5 deoxyribonucleic acid
HDL 5 high density lipoprotein
I 5 insertion
IVUS 5 intravascular ultrasound
LDL 5 low density lipoprotein
OR 5 odds ratio
PCR 5 polymerase chain reaction
Table 1. Basic Characteristics of 146 Patients by
Angiotensin-Converting Enzyme Insertion/Deletion* Genotype
ACE Genotype
DD
(n 5 46)
ID
(n 5 68)
II
(n 5 32)
Male/female 36/10 56/12 24/8
Age (yr) 61.3 6 9.4 58.0 6 8.5 62.6 6 7.4
BMI (kg/m2) 26.7 6 2.9 26.9 6 4.0 26.6 6 3.2
Never-smoker 15 21 10
Ex-smoker 20 29 16
Current smoker 11 18 6
Hx of MI 58% 60% 56%
Yes/no 27/19 41/27 18/14
Vessel disease
1 18 37 11
2 17 20 14
3 11 11 7
SBD (mm Hg) 135 6 21 132 6 17 138 6 15
DBP (mm Hg) 80 6 10 78 6 11 80 6 10
Total-C (mg/dl) 190 6 34 200 6 38 209 6 39
LDL-C (mg/dl) 114 6 30 126 6 37 124 6 33
HDL-C (mg/dl) 38 6 13 40 6 12 38 6 10
TGs (mg/dl)
Median 197 190 212
Range 73–600 64–436 60–589
Vessel examined
RCA 14 22 9
LAD 30 40 18
LCx 1 5 5
Venous graft 1 1
*No significant differences between groups, except for age, which is lower for
ID than for DD or II (p , 0.05). Data presented are mean value 6 SD or
number of patients, unless otherwise indicated. ACE 5 angiotensin-converting
enzyme; BMI 5 body mass index; D 5 deletion; DBP 5 diastolic blood pressure;
HDL-C 5 high density lipoprotein cholesterol; Hx 5 history; I 5 insertion;
LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary
artery; LDL-C 5 low density lipoprotein cholesterol; MI 5 myocardial infarc-
tion; RCA 5 right coronary artery; SBP 5 systolic blood pressure; TGs 5
triglycerides; Total-C 5 total cholesterol.
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and range for plasma triglyceride levels because of its skewed
distribution. The mean values for the three groups (DD, ID
and II) were compared by one-way analysis of variance or the
Kruskal-Wallis test (plasma triglycerides). Categoric data were
assessed using the likelihood ratio test. The analysis was also
carried out by means of an explorative multiple logistic regres-
sion analysis to assess the independent role of the different
factors possibly influencing lesion morphology, with the pres-
ence or absence of plaque calcification as dependent variable.
For this analysis, the continuous variables age; body mass
index; total plasma cholesterol level, HDL and LDL choles-
terol levels; and triglyceride levels were each grouped in
quartiles. In addition, for the ACE genotype, odds ratios were
calculated as a measure of the association with the plaque
calcification, with the effects of the D allele assumed to be
additive (with scores of 0, 1 and 2 for the II, ID and DD
genotypes, respectively), dominant (with scores of 0 for the II
genotypes and 1 for the ID and DD genotypes) or recessive
(with scores of 0 for the II and ID genotypes and 1 for the DD
genotypes). For each odds ratio, the 95% confidence intervals
and two-tailed p values were calculated. All analyses were done
with use of a personal computer with JMP 3.2 (SAS Institute).
A p value ,0.05 was considered statistically significant.
Results
The frequencies of the ACE genotypes (DD 46 [31.5%], ID
68 [46.6%] and II 32 [21.9%]) and the D allele (54%) in the
146 patients investigated were virtually identical to those
obtained in studies in Europe (1,7) and North America (6),
and the distribution was consistent with the study population
being in Hardy-Weinberg equilibrium. Thus, with respect to
the ACE gene locus, our sample is representative of white
populations. The genotype groups were well matched for
gender, body mass index and smoker status. Age was signifi-
cantly lower in the ID group than in the DD and II groups (p 5
0.02). Systolic and diastolic blood pressures did not differ
among the groups, and there were no significant differences in
plasma lipid and lipoprotein levels. The distribution of vessels
examined did not differ among the genotype groups (Table 1),
and there was no association between the ACE I/D genotype
and a history of myocardial infarction (odds ratio [OR] ad-
justed for age [DD vs. ID 1 II) 1.05, 95% confidence interval
[CI] 0.51 to 2.19, p 5 0.89).
Among the DD genotypes, we found significantly fewer
noncalcified lesions (Table 2). Eighty percent of patients with
the DD genotype had calcified lesions. In contrast, only 57% of
patients with ID genotype and 66% of patients with the II
genotype had calcified lesions (OR for DD vs. ID 1 II 2.88,
95% CI 1.30 to 6.92, p 5 0.008). Among patients with calcified
lesions, those with the DD genotype also had significantly
more severe calcifications, with shadowing of .180° of the
lumen circumference in 22% of the lesions compared with
10% of those with the ID genotype and 6% of those with the
II genotype (OR for DD vs. ID 1 II 2.80, 95% CI 1.05 to 7.63,
p 5 0.03). Thus, the DD genotype was associated not only with
the presence but also with the extent of coronary plaque
calcification. However, coronary plaque calcification, was not
significantly associated with a history of myocardial infarction
(OR for calcified vs. noncalcified lesions 1.44, 95% CI 0.72 to
2.88, p 5 0.31; OR adjusted for age 1.69, 95% CI 0.82 to 3.53,
p 5 0.16).
Because age and gender have been shown (16) to be the
most important risk factors for coronary calcification detected
by ultrafast computed tomography in asymptomatic men and
women, multiple logistic regression analysis was performed to
correct for these and other possible influencing factors. Age
was found to be the strongest predictor of coronary plaque
calcification (OR 6.03, 95% CI 1.87 to 21.47, p 5 0.003),
whereas gender, hypertension and a history of smoking were
not found to be predictive of plaque calcification (Table 3). In
Table 2. Intravascular Ultrasound Lesion Characteristics by
Angiotensin-Converting Enzyme Genotype
Echoreflectivity
of Plaque
ACE Genotype
DD
(n 5 46)
ID
(n 5 68)
II
(n 5 32)
Noncalcified lesions 9 (20%) 29 (43%) 13 (34%)
Poorly echoreflective 9 (20%) 25 (37%) 9 (28%)
Highly echoreflective 0 (0%) 4 (6%) 4 (6%)
Calcified lesions 37 (80%) 39 (57%) 21 (66%)
Calcification ,90° 16 (34%) 14 (21%) 8 (25%)
Calcification 90° to 180° 11 (24%) 18 (26%) 11 (34%)
Calcification .180° 10 (22%) 7 (10%) 2 (6%)
Data presented are number (%) of patients. Odds ratio 2.88 (95% confi-
dence interval [CI] 1.30 to 6.92, p 5 0.008) for calcified versus noncalcified
lesions (DD vs. ID 1 II); odds ratio 2.80 (95% CI 1.05 to 7.63, p 5 0.03) for
lesions with calcification .180° of target circumference versus lesions with less or
no calcification (DD vs. ID 1 II). Abbreviations as in Table 1.
Table 3. Odds Ratios for Intravascular Ultrasound Coronary Plaque
Calcification by ACE Genotype and Other Variables: Multiple
Logistic Regression Analysis*
Factor Chi-Square OR (95% CI) p Value
Age 9.29 6.03 (1.87–21.47) 0.0023
ACE DD genotype 7.93 3.69 (1.47–10.19) 0.0049
Male gender 0.93 1.70 (0.58–5.08) 0.34
Hx of MI 2.90 2.08 (0.90–4.98) 0.09
Hx of smoking 1.48 0.56 (0.21–1.42) 0.22
BMI 3.91 0.34 (0.11–0.99) 0.048
Diabetes 0.90 1.63 (0.60–4.71) 0.34
Hypertension† 0.03 0.92 (0.38–2.27) 0.86
Total-C 1.34 3.47 (0.43–30.68) 0.25
HDL-C 1.63 2.29 (0.64–8.61) 0.20
LDL-C 2.13 0.24 (0.03–1.63) 0.14
TGs 4.04 3.91 (1.04–15.79) 0.05
*Age, body mass index (BMI), total cholesterol (Total-C), high density
lipoprotein (HDL-C) and low density lipoprotein (LDL-C) cholesterol and
triglycerides (TGs) were grouped in quartiles. †Systolic blood pressure
.140 mm Hg, diastolic blood pressure .90 mm Hg, or both, at repeated
measurements or the current use of antihypertensive agents for a confirmed
diagnosis of arterial hypertension. CI 5 confidence interval; OR 5 odds ratio;
other abbreviations as in Table 1.
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addition to age, the ACE DD genotype again proved to be
associated with coronary plaque calcification (OR 3.69, 95%
CI 1.47 to 10.19, p 5 0.0049). There were also no significant
relations between coronary plaque calcification and a history of
myocardial infarction or plasma lipid and lipoprotein levels
(Table 3).
The analysis of the odds ratios between the presence or
absence of coronary plaque calcification and the three ACE
genotypes, adjusted for age, revealed a recessive effect of the D
allele with an adjusted OR of 2.62 in the model comparing the
DD genotypes with the ID and II genotypes (95% CI 1.16 to
6.42, p 5 0.02). Using the model for an additive effect of the D
allele, the adjusted odds ratio for the DD versus the ID
genotype was 2.72 (95% CI 1.15 to 6.92, p 5 0.02); for the ID
genotype versus the II genotype, the adjusted odds ratio was
0.88 (95% CI 0.35 to 2.18, p 5 0.79). In the model for the
dominant effect of the D allele, the adjusted odds ratio was
1.28 (95% CI 0.53 to 3.00, p 5 0.58) for the DD and ID
genotypes versus the II genotype.
Discussion
The results of the present study showed that the ACE DD
genotype is associated with the incidence and extent of coro-
nary calcification as assessed by IVUS. Although the major
determinant of coronary plaque calcification is age, the asso-
ciation with the ACE DD genotype persists after correction for
age and is stronger than the nonsignificant association between
history of myocardial infarction and coronary plaque calcifica-
tion.
IVUS and plaque calcification. The ability of IVUS to
characterize coronary plaque composition and calcification is
well documented (10–12). IVUS has been shown (17) to be
highly sensitive and specific in detecting dense, coherent
calcification in human coronary arteries compared with histo-
logic examination and to be far more sensitive than angiogra-
phy in the diagnosis of coronary calcification (12). The im-
proved characterization of coronary plaque morphology by
IVUS examination led to the finding of an association of
plaque calcification with the ACE gene D polymorphism,
which was not detected by coronary angiography. This obser-
vation could explain why the ACE gene polymorphism seemed
not to be associated with native CAD as determined by
coronary angiography, but with myocardial infarction in some
studies (2,8).
Plaque calcification and coronary events. One of the im-
portant findings of this study is the relatively low prevalence of
noncalcified lesions. This result is compatible with those in a
subgroup of patients with stable angina pectoris in a study (18)
using IVUS to identify unstable coronary lesions. However, the
inclusion of only patients with stable angina may be a selection
bias in the cohort investigated. Although patients with severe
coronary plaque calcification may be less prone to acute
coronary events than are patients with unstable lesions, the
frequency of stable lesions in patients who died abruptly of
myocardial infarction has been shown (19) to be ;50%. In
addition, the interface between a calcified region of coronary
plaque and the adjacent noncalcified region seems to be
exposed to increased mechanical shear stress, resulting in
plaque disruption (20). In agreement with these results, and in
concordance with the currently accepted theory of plaque
rupture, 59% of our patients had a history of myocardial
infarction. The increased frequency of calcified lesions among
patients with the ACE DD genotype could explain the recently
described observation that the beneficial effects of lipid-
lowering therapy on ischemic events and angiographically
defined coronary stenosis are blunted among patients with the
ACE DD genotype (21).
ACE polymorphism and plaque calcification. The signifi-
cant association of the ACE D polymorphism with coronary
plaque calcification is in accordance with the recent findings of
Rasmussen and Cedet (22), who described an increased extent
of macroscopically visible aortic atherosclerosis at autopsy in
both insulin-dependent and -independent diabetic patients
who were homozygous or heterozygous for the ACE D allele.
In that postmortem study, the ACE gene polymorphism was
not related to total collagen and type IV or V collagen,
indicating a possible involvement of the ACE gene polymor-
phism in the later stages of atherosclerosis.
In the past, coronary calcification has been regarded as a
passive process of adsorption or precipitation of calcium
phosphate crystals. Recently, coronary plaque calcification has
been recognized as an organized, regulated process (23).
Coronary calcification is absent in the normal arterial vessel
wall and seems to occur only late in the development in
atherosclerotic lesions (24). The influence of genetic factors on
the occurrence of arterial calcification has recently been shown
in genetically distinct inbred mice (25). Although the molecu-
lar basis for the incorporation of calcium and the extent of this
calcification is not completely understood, several proteins
involved in bone formation and calcification have been iden-
tified in atherosclerotic human coronary artery specimens (26).
One of these proteins, osteopontin, a phosphorylated glyco-
protein, has been shown (26) to be present at the calcification
front of atherosclerotic segments, and osteopontin mRNA
expression by macrophages has been demonstrated to be
related to the severity of atherosclerosis (27). In addition to
basic fibroblast growth factor and transforming growth factor-
beta, angiotensin II is known to increase the osteopontin
mRNA and protein expression in vascular smooth muscle cells
in vitro (28). Both circulating (29) and local (30) cardiac
activities of ACE are higher in the presence of the ACE gene
D polymorphism, which might increase the conversion of the
inactive angiotensin I to the highly active angiotensin II. Thus,
it can be speculated that in addition to its documented role in
vasoconstriction and vascular smooth muscle cell growth (31),
the renin-angiotensin system may also be involved in the
regulation of calcification in atherosclerotic arteries.
Study limitations. This study is limited by the possible
selection bias due to the inclusion of only patients with stable
angina and to the relatively low number of patients. The
number of patients examined was too low to find or exclude
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associations between ACE I/D gene polymorphism and myo-
cardial infarction, so the relation among ACE polymorphism,
coronary plaque calcification and myocardial infarction re-
mains somewhat speculative. In addition, the lack of associa-
tion among the plasma lipids, hypertension and diabetes on the
coronary plaque morphology must be interpreted with caution
because the duration and modification of these risk factors
were not known. Furthermore, the mechanisms by which the
intronic ACE I/D polymorphism could influence coronary
plaque calcification are hypothetic. Probably, the ACE I/D
polymorphism is only a marker for the functional polymor-
phism or mutation that influences coronary plaque calcifica-
tion, so the linkage disequilibrium between the two polymor-
phisms may be limited to the cohort examined. However, an
association between the ACE I/D gene polymorphism and the
carotid artery wall thickness has recently been reported (32) in
an ethnically distinct group of Japanese patients with non–
insulin-dependent diabetes mellitus, indicating an involvement
of this ACE polymorphism in the development or progression
of atherosclerosis in different populations and vessel regions.
Conclusions. The findings of the present study suggest that
in addition to age, the ACE DD genotype is an independent
determinant of the incidence and extent of coronary plaque
calcification in patients with stable angina pectoris. This ob-
servation is a possible explanation for the increased risk of
cardiovascular events in patients with CAD who have the ACE
DD genotype.
References
1. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for
angiotensin-converting enzyme is a potent risk factor for myocardial infarc-
tion. Nature 1992;359:641–4.
2. Wang XL, McCredie RM, Wilcken DEL. Genotype distribution of
angiotensin-converting enzyme polymorphism in Australian healthy and
coronary populations and relevance to myocardial infarction and coronary
artery disease. Arterioscler Thromb Vasc Biol 1996;16:115–9.
3. Nakai K, Itoh C, Miura Y, et al. Deletion polymorphism of the angiotensin
I-converting enzyme gene is associated with serum ACE concentration and
increased risk for CAD in the Japanese. Circulation 1994;90:2199–202.
4. Ruiz J, Blanche H, Cohen N, et al. Insertion/deletion polymorphism of the
angiotensin-converting enzyme gene is strongly associated with coronary
heart disease in non–insulin-dependent diabetes mellitus. Proc Natl Acad Sci
USA 1994;91:3662–5.
5. Mattu RK, Needham EW, Galton DJ, Frangos E, Clark AJ, Caulfield M. A
DNA variant at the angiotensin-converting enzyme gene locus associates
with coronary artery disease in the Caerphilly Heart Study. Circulation
1995;91:270–4.
6. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an
angiotensin-converting-enzyme gene polymorphism and the risk of ischemic
heart disease. N Engl J Med 1995;332:706–11.
7. Friedl W, Krempler F, Paulweber B, Pichler M, Sandhofer F. A deletion
polymorphism in the angiotensin converting enzyme gene is not associated
with coronary heart disease in an Austrian population. Atherosclerosis
1995;112:137–43.
8. Ludwig E, Corneli PS, Anderson JL, Marshall HW, Lalouel JM, Ward RH.
Angiotensin-converting enzyme gene polymorphism is associated with myo-
cardial infarction but not with development of coronary stenosis. Circulation
1995;91:2120–4.
9. Singer DRJ, Missouris CG, Jeffery S. Angiotensin-converting enzyme poly-
morphism: what to do about all the confusion? Circulation 1996;94:236–9.
10. Mintz GS, Popma JJ, Pichard AD, et al. Limitations of angiography in the
assessment of plaque distribution in coronary artery disease: a systematic
study of target lesion eccentricity in 1446 lesions. Circulation 1996;93:924–
31.
11. Kimura BJ, Bhargava V, DeMaria AN. Value and limitations of intravascu-
lar ultrasound imaging in characterizing coronary atherosclerotic plaque.
Am Heart J 1995;130:386–96.
12. Mintz GS, Popma JJ, Pichard AD, et al. Patterns of calcification in coronary
artery disease: a statistical analysis of intravascular ultrasound and coronary
angiography in 1155 lesions. Circulation 1995;91:1959–65.
13. Detrano R, Hsiasi T, Wang S, et al. Prognostic value of coronary calcification
and angiographic stenoses in patients undergoing coronary arteriography.
J Am Coll Cardiol 1996;27:285–90.
14. Koch M, Lehmann R, Pfohl M, Voelter W, Liebich H. Analysis of the
deletion/insertion polymorphism of the angiotensin I-converting enzyme
gene by capillary electrophoresis. Clin Chim Acta 1996;248:197–203.
15. Shanmugan V, Sell KW, Saha K. Mistyping ACE heterozygotes. PCR
Methods Appl 1993;3:120–1.
16. Goel M, Wong ND, Eisenberg H, Hagar J, Kelly K, Tobis JM. Risk factor
correlates of coronary calcium as evaluated by ultrafast computed tomogra-
phy. Am J Cardiol 1992;70:977–90.
17. Friedrich GJ, Moes NY, Muhlberger VA, et al. Detection of intralesional
calcium by intracoronary ultrasound depends on the histologic pattern. Am
Heart J 1994;128:435–41.
18. Hodgson JM, Reddy KG, Suneja R, Nair RN, Lesnefsky EJ, Sheehan HM.
Intracoronary ultrasound imaging: correlation of plaque morphology with
angiography, clinical syndrome and procedural results in patients undergoing
coronary angioplasty. J Am Coll Cardiol 1993;21:35–44.
19. Farb A, Tang AL, Burke AP, Sessums L, Liang Y, Virmani R. Sudden
coronary death: frequency of active coronary lesions, inactive coronary
lesions, and myocardial infarction. Circulation 1995;92:1701–9.
20. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation
1995;92:657–71.
21. Rasmussen LM, Ledet T. Aortic atherosclerosis in diabetes mellitus is
associated with an insertion/deletion polymorphism in the angiotensin
I-converting enzyme gene. Diabetologia 1996;39:696–700.
22. Van Geel PP, Pinto YM, Zwinderman AH, et al. The angiotensin-converting
enzyme deletion-type gene is associated with ischemic events and a blunted
effect of lipid-lowering treatment on angiographically defined coronary
atherosclerosis [abstract]. Eur Heart J 1997;18 Suppl:141.
23. Wrexler L, Brundage B, Crouse J, et al. Coronary artery calcification:
pathophysiology, epidemiology, imaging methods, and clinical implications.
Circulation 1996;94:1175–92.
24. Simons DB, Schwartz RS, Edwards WD, Sheedy PF, Breen JF, Rumberger
JA. Noninvasive definition of anatomic coronary artery disease by ultrafast
computed tomographic scanning: a quantitative pathologic comparison
study. J Am Coll Cardiol 1992;20:1118–26.
25. Qiao JH, Xie PZ, Fishbein MC, et al. Pathology of atheromatous lesions in
inbred and genetically engineered mice: genetic determination of arterial
calcification. Arterioscler Thromb 1994;14:1480–97.
26. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcification
in human coronary arteries: association of osteopontin with atherosclerosis.
J Clin Invest 1994;94:1597–604.
27. Hirota S, Imakita M, Kohri K, et al. Expression of osteopontin messenger
RNA by macrophages in atherosclerotic plaques: a possible association with
calcification. Am J Pathol 1993;143:1003–8.
28. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM.
Osteopontin is elevated during neointima formation in rat arteries and is a
novel component of human atherosclerotic plaques. J Clin Invest 1993;92:
1686–96.
29. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An
insertion/deletion polymorphism in angiotensin I converting enzyme gene
accounting for half of the variance of serum enzyme levels. J Clin Invest
1990;86:1343–6.
30. Danser JAH, Schalekamp MADH, Bax WA, et al. ACE in the human heart:
effect of the deletion/insertion polymorphism. Circulation 1995;92:1387–8.
31. Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II
induces smooth muscle cell proliferation in the normal and injured rat
arterial wall. Circ Res 1991;68:450–68.
32. Hosoi M, Nishizawa Y, Kogawa K, et al. Angiotensin-converting enzyme
gene polymorphism is associated with carotid arterial wall thickness in
non–insulin-dependent diabetic patients. Circulation 1996;94:704–7.
991JACC Vol. 31, No. 5 PFOHL ET AL.
April 1998:987–91 ACE POLYMORPHISM AND CORONARY ARTERY CALCIFICATION
